BASEL, SWITZERLAND--(Marketwired - April 09, 2013) - Basilea Pharmaceutica Ltd. (SIX: BSLN)
reported that shareholders approved all agenda items proposed at today's
Ordinary General Meeting of Shareholders for the financial year 2012. At
meeting, 59.9 percent of Basilea's share capital was represented.
The shareholders approved the annual report, the financial statements and
consolidated financial statements for the business year 2012, and
members of the Board of Directors and Management. Shareholders also
carrying forward the accumulated deficit.
In addition, Dr. Martin Nicklasson was elected to the Board of Directors
term of three years. Basilea's Board of Directors now comprises seven
non-executive members: Dr. Martin Nicklasson, Mr. Hans-Beat Gürtler,
Lew, Dr. Thomas M. Rinderknecht, Mr. Domenico Scala, Mr. Steven D. Skolsky
Dr. Thomas Werner. The Board of Directors elected Dr. Nicklasson as
the Board and Domenico Scala as Vice-Chairman.
The shareholders re-elected PricewaterhouseCoopers AG, Basel, as Statutory
Auditors for the audit of the stand-alone and the consolidated financial
statements for the business year 2013.
Basilea's shareholders approved the proposal of HBM Healthcare Investments
(Cayman) Ltd., holding 24.97 percent of the company's shares, to distribute
5.00 per share corresponding to approximately CHF 48 million from capital
contribution reserves to shareholders. The payment will be made on June
21, 2013. The last trading day to participate in the distribution will be
April 10, 2013. Starting from the ex-date of April 11, 2013, Basilea shares
be traded without the right to participate in the distribution.
In his presentation to shareholders, Chief Executive Officer Ronald Scott
stated: "We achieved significant milestones in 2012 and successfully
our core area of overcoming resistance in anti-infectives and oncology. The
company is uniquely positioned to potentially create significant value for
shareholders as we move closer to the important milestones in the second
this year: the potential approval of our antibiotic ceftobiprole in Europe
well as the first phase 3 results for our antifungal isavuconazole."
The Board and Management expressed their sincere thanks to the retiring
members Werner Henrich, Chairman since the company's inception, and Claude
Schreiner, Board Member since 2007, for their invaluable contributions.
Ronald Scott commented: "With his strategic vision, extensive experience in
deal-making and outstanding commitment, Werner Henrich has passionately
as our Chairman to build and grow the company for more than a decade.
Schreiner's wide-ranging industry experience was instrumental in creating
significant value of Toctino which we were able to achieve for shareholders
through our transaction with Stiefel/GSK last year."
With the addition of Dr. Nicklasson to the Board, the Board is convinced
Basilea is well positioned to continue its path as one of the leading
biopharmaceutical companies addressing the growing medical need of drug
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and
the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research
development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd., the Company focuses on innovative pharmaceutical
the therapeutic areas of bacterial infections, fungal infections and
targeting the medical challenge of rising resistance and non-response to
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
or achievements of Basilea Pharmaceutica Ltd. to be materially different
any future results, performance or achievements expressed or implied by
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.
This press release can be downloaded from www.basilea.com.
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE